Literature DB >> 34595582

Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders.

Kaitlyn Koenig Thompson1, Stella E Tsirka2.   

Abstract

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) characterized by peripheral immune cell infiltration into the brain and spinal cord, demyelination, glial cell activation, and neuronal damage. Currently there is no cure for MS, however, available disease-modifying agents minimize inflammation in the CNS by various mechanisms. Approved drugs lessen severity of the disease and delay disease progression, however, they are still suboptimal as patients experience adverse effects and varying efficacies. Additionally, there is only one disease-modifying therapy available for the more debilitating, progressive form of MS. This chapter focuses on the presently-available therapeutics and, importantly, the future directions of MS therapy based on preclinical studies and early clinical trials. Immunosuppression in other neurological disorders including neuromyelitis optica spectrum disorders, myasthenia gravis, and Guillain-Barré syndrome is also discussed.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Autoimmunity; Disease-modifying therapies; Guillain-Barré syndrome; Immunosuppression; Multiple sclerosis; Myasthenia gravis; Neuromyelitis optica

Mesh:

Year:  2022        PMID: 34595582     DOI: 10.1007/164_2021_545

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  104 in total

1.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Authors:  Bibiana Bielekova; Marta Catalfamo; Susan Reichert-Scrivner; Amy Packer; Magdalena Cerna; Thomas A Waldmann; Henry McFarland; Pierre A Henkart; Roland Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

2.  Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool.

Authors:  Bahareh Ajami; Jami L Bennett; Charles Krieger; Kelly M McNagny; Fabio M V Rossi
Journal:  Nat Neurosci       Date:  2011-07-31       Impact factor: 24.884

Review 3.  Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.

Authors:  Laura E Baldassari; John W Rose
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 4.  Potential mechanisms of action related to the efficacy and safety of cladribine.

Authors:  David Baker; Gareth Pryce; Samuel S Herrod; Klaus Schmierer
Journal:  Mult Scler Relat Disord       Date:  2019-02-14       Impact factor: 4.339

5.  Neuromyelitis optica treatment: analysis of 36 patients.

Authors:  Denis Bernardi Bichuetti; Enedina Maria Lobato de Oliveira; Daniel May Oliveira; Nilton Amorin de Souza; Alberto Alain Gabbai
Journal:  Arch Neurol       Date:  2010-09

6.  Cellular immune response in multiple sclerosis plaques.

Authors:  E A Boyle; P L McGeer
Journal:  Am J Pathol       Date:  1990-09       Impact factor: 4.307

7.  Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.

Authors:  Shaul Beyth; Zipora Borovsky; Dror Mevorach; Meir Liebergall; Zulma Gazit; Hadi Aslan; Eithan Galun; Jacob Rachmilewitz
Journal:  Blood       Date:  2004-10-28       Impact factor: 22.113

8.  Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study.

Authors:  Mandana Mohyeddin Bonab; Mohammad Ali Sahraian; Aida Aghsaie; Sanaz Ahmadi Karvigh; Seyed Massoud Hosseinian; Behrouz Nikbin; Jamshid Lotfi; Saeideh Khorramnia; Mohammad Reza Motamed; Mansoureh Togha; Mohammad Hossien Harirchian; Nahid Beladi Moghadam; Katayoun Alikhani; Samira Yadegari; Sirous Jafarian; Mohammad Reza Gheini
Journal:  Curr Stem Cell Res Ther       Date:  2012-11       Impact factor: 3.828

Review 9.  The Guillain-Barré syndrome: a true case of molecular mimicry.

Authors:  C Wim Ang; Bart C Jacobs; Jon D Laman
Journal:  Trends Immunol       Date:  2004-02       Impact factor: 16.687

10.  Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.

Authors:  Harold L Atkins; Marjorie Bowman; David Allan; Grizel Anstee; Douglas L Arnold; Amit Bar-Or; Isabelle Bence-Bruckler; Paul Birch; Christopher Bredeson; Jacqueline Chen; Dean Fergusson; Mike Halpenny; Linda Hamelin; Lothar Huebsch; Brian Hutton; Pierre Laneuville; Yves Lapierre; Hyunwoo Lee; Lisa Martin; Sheryl McDiarmid; Paul O'Connor; Timothy Ramsay; Mitchell Sabloff; Lisa Walker; Mark S Freedman
Journal:  Lancet       Date:  2016-06-09       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.